IBIO logo

iBio (IBIO) Company Overview

Profile

Full Name:

iBio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

August 19, 2008

Indexes:

Not included

Description:

iBio is a biotechnology company that focuses on developing and producing plant-based therapies and vaccines. They use a unique technology to create proteins quickly and efficiently, aiming to improve healthcare solutions for various diseases. Their innovative approach helps in making treatments more accessible and affordable.

Events Calendar

Earnings

Next earnings date:

Feb 7, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Sep 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 29, 2023

Analyst ratings

Recent major analysts updates

Dec 17, 24 LUCID CAPITAL MARKETS
Buy
Jul 22, 24 Brookline Capital
Buy
Jun 3, 24 Chardan Capital
Buy
May 28, 24 Chardan Capital
Buy
Oct 7, 22 Cantor Fitzgerald
Neutral
Nov 29, 21 JMP Securities
Outperform
Jan 22, 21 Cantor Fitzgerald
Overweight
Jan 21, 21 Cantor Fitzgerald
Overweight
Jun 26, 20 Alliance Global Partners
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
IBIO
globenewswire.comSeptember 20, 2024

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
IBIO
InvestorPlaceApril 5, 2024

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.

iBio stock nearly tripled on Wednesday: here's why
iBio stock nearly tripled on Wednesday: here's why
iBio stock nearly tripled on Wednesday: here's why
IBIO
InvezzMarch 27, 2024

Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.

iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
IBIO
Proactive InvestorsMarch 27, 2024

iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.

Why Is iBio (IBIO) Stock Up 125% Today?
Why Is iBio (IBIO) Stock Up 125% Today?
Why Is iBio (IBIO) Stock Up 125% Today?
IBIO
InvestorPlaceMarch 27, 2024

iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.

Why Is iBio (IBIO) Stock Down 41% Today?
Why Is iBio (IBIO) Stock Down 41% Today?
Why Is iBio (IBIO) Stock Down 41% Today?
IBIO
InvestorPlaceDecember 5, 2023

Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.

Why Is iBio (IBIO) Stock Up 16% Today?
Why Is iBio (IBIO) Stock Up 16% Today?
Why Is iBio (IBIO) Stock Up 16% Today?
IBIO
InvestorPlaceJune 13, 2023

Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).

FAQ

  • What is the ticker symbol for iBio?
  • Does iBio pay dividends?
  • What sector is iBio in?
  • What industry is iBio in?
  • What country is iBio based in?
  • When did iBio go public?
  • Is iBio in the S&P 500?
  • Is iBio in the NASDAQ 100?
  • Is iBio in the Dow Jones?
  • When was iBio's last earnings report?
  • When does iBio report earnings?
  • Should I buy iBio stock now?

What is the ticker symbol for iBio?

The ticker symbol for iBio is NYSE American:IBIO

Does iBio pay dividends?

No, iBio does not pay dividends

What sector is iBio in?

iBio is in the Healthcare sector

What industry is iBio in?

iBio is in the Biotechnology industry

What country is iBio based in?

iBio is headquartered in United States

When did iBio go public?

iBio's initial public offering (IPO) was on August 19, 2008

Is iBio in the S&P 500?

No, iBio is not included in the S&P 500 index

Is iBio in the NASDAQ 100?

No, iBio is not included in the NASDAQ 100 index

Is iBio in the Dow Jones?

No, iBio is not included in the Dow Jones index

When was iBio's last earnings report?

iBio's most recent earnings report was on Nov 12, 2024

When does iBio report earnings?

The next expected earnings date for iBio is Feb 7, 2025

Should I buy iBio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions